Clinical Trials on Rhegmatogenous Macula-off Retinal Detachment in Russian Federation

Total 51 results

The S.N. Fyodorov Eye Microsurgery State Institution

Unknown

Combined Laser-surgical Technology of RRD Treatment

Rhegmatogenous Retinal Detachment

Russian Federation
The S.N. Fyodorov Eye Microsurgery State Institution

Unknown

Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery.

Retinal Detachment

Russian Federation
The S.N. Fyodorov Eye Microsurgery State Institution

Completed

Microarchitecture of Vitreoretinal Contact

Vitreoretinal Detachment | Vitreo-Retinal Adhesion

Russian Federation
Russian Academy of Medical Sciences

Unknown

Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Russian Federation
The S.N. Fyodorov Eye Microsurgery State Institution

Completed

Development of an Optimal Algorithm for the Management of Patients With Retinal Pigment Epithelium Detachment in Neovascular Age-related Macular Degeneration Using Artificial Intelligence

Neovascular Age-related Macular Degeneration

Russian Federation
The S.N. Fyodorov Eye Microsurgery State Institution
Makarenko Irina Romanovna; Zgoba Mariana Igorevna

Recruiting

Intraoperative Analysis of the Central Retina in ERF

Epiretinal Membrane | Macular Pucker

Russian Federation
Bayer
Regeneron Pharmaceuticals

Completed

Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy (POLARIS)

Macular Degeneration | Macular Edema | Ophthalmology

Slovakia, France, Germany, Spain, Russian Federation, United Kingdom, Portugal, Greece
Progen Pharmaceuticals

Completed

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Age Related Macular Degeneration

United States, Mexico, Russian Federation
AO GENERIUM

Recruiting

Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® (NAP)

Age Related Macular Degeneration (ARMD)

Russian Federation
Ural State Medical University
Ural Institute of Cardiology; De Haar Research Foundation

Terminated

Ranibizumab and the Risk of Arterial Thromboembolic Events (RATE)

Coronary Artery Disease | Cerebrovascular Disorders | Age-related Macular Degeneration

Netherlands, Russian Federation
Biocad

Withdrawn

Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration (GALATIR)

Wet Age-related Macular Degeneration

Brazil, Russian Federation
Bayer
Regeneron Pharmaceuticals

Completed

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease (AURIGA)

Macular Edema

Germany, Italy, Russian Federation, Taiwan, China, Egypt, France, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates
Bayer
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement (VIVID EAST)

Macular Edema

China, Hong Kong, Korea, Republic of, Russian Federation
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Poland, United States, Croatia, Japan, Russian Federation
I.M. Sechenov First Moscow State Medical University

Completed

Periodontal Disease in Patients With Obstructive Sleep Apnea

Periodontal Diseases | Obstructive Sleep Apnea of Adult | Periodontal Pocket | Periodontal Attachment Loss

Russian Federation
CoMentis

Terminated

Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

Macular Degeneration

Brazil, Mexico, Czech Republic, Poland, Russian Federation, Ukraine
Bioeq GmbH

Completed

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (COLUMBUS-AMD)

Age-related Macular Degeneration (AMD)

France, Italy, Poland, Russian Federation, Spain, United Kingdom, Germany, Hungary, Ukraine, Austria, Czechia, Israel
Bioeq GmbH

Completed

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)

Neovascular Age-related Macular Degeneration

Bulgaria, Italy, Poland, Russian Federation, Hungary, Ukraine, Japan, Israel, Czechia
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Korea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
Mylan Pharmaceuticals Inc
Momenta Pharmaceuticals, Inc.

Completed

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME) (DME)

Diabetic Macular Edema

Japan, United States, Czechia, Germany, Hungary, India, Latvia, Poland, Russian Federation
Novartis Pharmaceuticals

Completed

To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

Macular Edema (ME)

Russian Federation, Turkey, United Kingdom, Belgium, Australia, Hungary, Switzerland, Germany, Italy, Korea, Republic of, Israel, Spain, France, Latvia, Netherlands, Slovakia, Czech Republic, Singapore, Canada
Sam Chun Dang Pharm. Co. Ltd.

Completed

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States, Australia, Bulgaria, Czechia, Hungary, India, Israel, Japan, Korea, Republic of, Latvia, Poland, Russian Federation, Slovakia, Spain
Xbrane Biopharma AB
Stada Arzneimittel AG

Completed

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD (XPLORE)

Macular Degeneration

Israel, Spain, Hungary, United States, Slovakia, Lithuania, Bulgaria, Czechia, Estonia, India, Latvia, Poland, Romania, Russian Federation, Ukraine
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Diabetic Macular Edema

United States, Japan, Israel, Austria, France, Germany, Hungary, Italy, Mexico, Poland, Slovakia, Spain, Russian Federation, Bulgaria, Turkey, Peru
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)

Diabetic Macular Edema

United States, Korea, Republic of, United Kingdom, Brazil, China, Canada, Argentina, Australia, Denmark, France, Italy, Poland, Spain, Germany, Singapore, Czechia, Hong Kong, Portugal, Russian Federation, Taiwan, Hungary, Switzerland and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

Neovascular Age-related Macular Degeneration

United States, Korea, Republic of, United Kingdom, Japan, Canada, Turkey, Argentina, Australia, Denmark, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Brazil, Hong Kong, Israel, Portugal, Russian Federation, Ta... and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)

Diabetic Macular Edema

United States, Korea, Republic of, United Kingdom, Brazil, Japan, Canada, Argentina, Australia, Austria, Denmark, France, Germany, Hungary, Italy, Poland, Slovakia, Spain, Singapore, Czechia, Hong Kong, Israel, Portugal, Russian Federation and more
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Wet Macular Degeneration

United Kingdom, Germany, Japan, Netherlands, United States, Canada, Hungary, Italy, Mexico, Poland, Spain, Israel, Russian Federation, Switzerland, Turkey
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

Wet Macular Degeneration

Korea, Republic of, United States, China, Argentina, Australia, Denmark, France, Germany, Italy, Poland, Spain, Singapore, Austria, Brazil, Hong Kong, Hungary, Portugal, Russian Federation, Taiwan, Turkey, Bulgaria
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE)

Diabetic Macular Edema

Czechia, India, Russian Federation, Taiwan, Turkey, Lebanon, Denmark, Estonia, France, Germany, Hungary, Korea, Republic of, Latvia, Lithuania, Bulgaria, Norway, Belgium, Malaysia, Sweden, Slovakia, Singapore, Poland, Switzerland
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

Spain, Korea, Republic of, Czechia, Japan, Singapore, United States, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Portugal, Bulgaria, Latvia, Canada, Hungary, Arge... and more
Allergan

Completed

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Macular Degeneration

United States, Japan, United Kingdom, Italy, Taiwan, Australia, Canada, Hungary, Poland, Russian Federation, Netherlands, Brazil, Denmark, Peru, South Africa, Turkey
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more
Hoffmann-La Roche

Terminated

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)

Geographic Atrophy

United States, United Kingdom, Netherlands, Germany, Belgium, Poland, Spain, Argentina, Australia, Hungary, Italy, Portugal, France, Turkey, Austria, Russian Federation, Mexico, Peru, Denmark, Slovakia, Sweden, Switzerland
Novartis Pharmaceuticals

Completed

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (TREND)

Age-related Macular Degeneration | Choroidal Neovascularization

Korea, Republic of, Croatia, Germany, India, Russian Federation, Turkey, United Kingdom, Egypt, Israel, Belgium, Denmark, Hungary, Slovenia, Spain, Switzerland, Italy, Portugal, Slovakia, Chile
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)

Macular Edema | Branch Retinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Germany, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)

Central Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein Occlusion

United States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)

Branch Retinal Vein Occlusion

China, Austria, Czechia, Russian Federation, Taiwan, United Kingdom, Canada, Japan, United States, France, Israel, Germany, Italy, Hong Kong, Spain, Denmark, Slovakia, Puerto Rico, Switzerland
Novartis Pharmaceuticals

Terminated

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Central Retinal Vein Occlusion

China, Czechia, Germany, Russian Federation, Turkey, United States, Australia, Canada, Spain, United Kingdom, Thailand, Israel, Netherlands, Italy, Hungary, France, Greece, Puerto Rico, Malaysia, Japan
Chromaderm, Inc.

Completed

Reduction in the Occurrence of Center-Involved Diabetic Macular Edema

Diabetic Retinopathy

United States, Canada, France, Denmark, Australia, Netherlands, Taiwan, Spain, Italy, Germany, Portugal, United Kingdom, Russian Federation, Poland, India, Brazil, Mexico
Regeneron Pharmaceuticals

Enrolling by invitation

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

Retinopathy of Prematurity

United States, Bulgaria, Colombia, Korea, Republic of, Romania, Russian Federation, Taiwan, Thailand, Turkey, Vietnam
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy (FIREFLEYE)

Retinopathy of Prematurity (ROP)

Spain, Singapore, Hong Kong, Korea, Republic of, Malaysia, Japan, Taiwan, Sweden, Portugal, Belgium, Argentina, Bulgaria, Italy, Austria, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Poland, Romania, Russian Federation, Slov... and more
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (FIREFLEYE next)

Retinopathy of Prematurity (ROP)

Spain, Korea, Republic of, Singapore, Malaysia, Japan, Taiwan, Bulgaria, Italy, Argentina, Czechia, Greece, Israel, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Sweden, Turkey, United Kingdom, Ukraine, Hungary, Belgium and more
Ipsen

Completed

Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq (OPTIMA)

Renal Insufficiency, Chronic | Pituitary Diseases | Dwarfism | Turner Syndrome

France, Germany, Finland, Spain, Belgium, Czechia, Denmark, Greece, Italy, Romania, Russian Federation, Slovakia, Ukraine, United Kingdom
Regeneron Pharmaceuticals

Completed

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (BUTTERFLEYE)

Retinopathy of Prematurity

United States, Bulgaria, Hungary, Russian Federation, Thailand, Turkey, Colombia, Czechia, Korea, Republic of, Romania, Slovakia, Taiwan, Vietnam
Novartis Pharmaceuticals

Completed

Rainbow Extension Study (RainbowExt)

Retinopathy of Prematurity (ROP)

United States, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Romania, Russian Federation, Saudi Arabia, Slovakia, Taiwan, Turkey, United Kingdom, Lithuania, Estonia
Novo Nordisk A/S

Completed

Observational Prospective Study on Patients Treated With Norditropin®

Chronic Kidney Disease | Turner Syndrome | Noonan Syndrome | Chronic Renal Insufficiency | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency | Genetic Disorder | Foetal Growth Problem | Small for Gestational Age

Israel, Saudi Arabia, Spain, Argentina, Russian Federation, Germany, Netherlands, Italy, Belgium, United Kingdom, Slovenia, Ireland, Sweden, Denmark, Hungary, Finland, Norway, France, Czechia, Lithuania, Luxembourg, Serbia, Switzerland
Novartis Pharmaceuticals

Completed

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (RAINBOW)

Retinopathy of Prematurity

United States, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hungary, India, Italy, Japan, Lithuania, Malaysia, Mexico, Poland, Romania, Russian Federation, Saudi Arabia, Slovakia, Taiwan, Turkey, United...
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation

Completed

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

Chronic Kidney Disease

United States, Poland, Ukraine, Spain, Argentina, Mexico, Canada, Brazil, Russian Federation, Puerto Rico, Germany, Czechia
Bayer

Completed

Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis (CONVERT)

Hemodialysis | End-stage Renal Disease | Hemodiafiltration | Prevention of Thromboembolic Events

Spain, Greece, Belgium, Russian Federation, Netherlands, Turkey, Japan, Australia, Austria, Bulgaria, Italy, Ukraine, Czechia, Israel, United States, Hungary, Lithuania, Poland, Portugal

Clinical Trials on Rhegmatogenous Macula-off Retinal Detachment in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations